Dr Nathalie MAUBON

CEO/CSO

France

Research Interests

drug discovery, High Content Screening, Cell imaging, 3D culture, Extracellular Matrix

In HCS Pharma, we work with new technologies to develop new tools for drug discovery process. First, we have internalised a new 3D groundbreaking technology named BIOMIMESYS that allow us to reproduces faithfully organ-specific Extracellular Matrix in a innovative way. Second, we use iPSC différentiated in BIOMIMESYS to have more relevant tools as human cell sources. Third, we work with academic researcher on Organ-on-Chip tools woth BIOMIMESYS to develop dynamic 3D tissue as innovative tools for secondary screening.